Accelerate Diagnostics Inc. (NASDAQ:AXDX) rose 1.2% on Wednesday . The company traded as high as $21.98 and last traded at $21.91, with a volume of 122,936 shares trading hands. The stock had previously closed at $21.64.

AXDX has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. raised their price objective on Accelerate Diagnostics from $17.00 to $25.00 and gave the company an “overweight” rating in a research note on Tuesday, August 9th. BTIG Research upgraded Accelerate Diagnostics from a “neutral” rating to a “buy” rating in a research note on Thursday, August 25th. Zacks Investment Research upgraded Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research note on Monday. Finally, Piper Jaffray Cos. restated an “overweight” rating and set a $25.00 price objective on shares of Accelerate Diagnostics in a research note on Monday, May 16th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Accelerate Diagnostics has a consensus rating of “Buy” and a consensus price target of $25.33.

The stock’s market capitalization is $1.12 billion. The company has a 50-day moving average of $20.86 and a 200 day moving average of $15.32.

In other news, Director Jack W. Schuler acquired 90,147 shares of Accelerate Diagnostics stock in a transaction that occurred on Thursday, June 30th. The stock was purchased at an average price of $13.95 per share, with a total value of $1,257,550.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jack W. Schuler acquired 101,272 shares of Accelerate Diagnostics stock in a transaction that occurred on Thursday, June 9th. The shares were purchased at an average cost of $14.14 per share, with a total value of $1,431,986.08. The disclosure for this purchase can be found here.

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.